[{"Assets_0_Q2_USD":73805000.0,"CommonStockSharesOutstanding_0_Q2_shares":157437000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-10082000.0,"NetIncomeLoss_1_Q2_USD":-4520000.0,"NetIncomeLoss_2_Q2_USD":-10713000.0,"StockholdersEquity_0_Q2_USD":24646000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":14162000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":26865000.0,"Ticker":"ATRS","CIK":"1016169","name":"ANTARES PHARMA, INC.","OfficialName":"Antares Pharma Inc. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"948492298.0","Country":"United States","Sector":"Health Care","Industry":"Medical\/Dental Instruments","Market":"NASDAQ","SP500":"nan","filed":"20180807"}]